Prakt. lékáren. 2010; 6(1): 9-14

Benign prostatic hyperplasia, diagnostics and contemporary opportunities of miniinvasive treatment

MUDr.Jiří Klečka, Ph.D., MUDr.Petr Běhounek, doc.MUDr.Milan Hora, Ph.D., MUDr.Viktor Eret
Urologická klinika FN a LF UK v Plzni

This article summarizes contemporary oppurtunities of miniinvasive treatment of the patients with benign prostate hyperplasia (BPH).

Uptodate pharmacological treatment offers to the patients good quality of life and decreased the risk of surgical intervention. Nowadays

is very popular combined therapy mainly combination of alpha-adrenergic blockers with 5α-reductase inhibitors or with parasympatolytics.

Keywords: benign prostatic hyperplasia, alpha-adrenergic blockers, 5α-reductase inhibitors, parasympatolytics, 5-phosphodiesterase

Published: March 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klečka J, Běhounek P, Hora M, Eret V. Benign prostatic hyperplasia, diagnostics and contemporary opportunities of miniinvasive treatment. Pharmacy for Practice. 2010;6(1):9-14.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Roehrborn C, McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh P, Retik A, Vaughan E, Wein A, eds. Campbell's Urology. Sth ed. Philadelphia: Saunders; 2002: 1297-1336.
    2. Girman CJ. Population-based studies of the epidemiology of benign prostatic hyperplasia. Br J Urol. 1998; 82(suppl. 1): 34-43. Go to original source... Go to PubMed...
    3. Girman CJ, Jacobsen SJ, Rhodes T, et al. Association of health-related quality of life and benign prostatic enlargement. Eur Urol. 1999; 35: 277-284. Go to original source... Go to PubMed...
    4. Girman CJ, Jacobsen SJ, Tsukarnoto T, et al. Health-related quality of life associated with lower urinary tract symptorns iri four countries. Urology. 1998: 51: 428-436. Go to original source... Go to PubMed...
    5. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003: 44: 637-649. Go to original source... Go to PubMed...
    6. United Nations. World Population Prospects: The 2002 Revision (medium scenarío). New York: United Nations, 2003.
    7. American Urological Association Practice Guidelines Committee. AUA guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 2003: 170(2 Pt 1): 530-547. Go to PubMed...
    8. Roehrborn CG, Girman CJ, Rhodes T, et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology. 1997: 49: 548-557. Go to original source... Go to PubMed...
    9. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Cornmittee of the American Urological Association. J Urol. 1992: 148: 1549-1557; discussion 1564. Go to original source... Go to PubMed...
    10. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. Measuring diseasespecific health status in men with benign prostatic hyperplasia. Measuremerit Committee of the American Urological Association. Med Care. 1995: 33(4 suppl): AS145-AS155.
    11. Rosen RC, Cappelleri JC, Gendrario N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int. J Impot Res. 2002: 14: 226-244. Go to original source... Go to PubMed...
    12. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999: 11: 319-326. Go to original source... Go to PubMed...
    13. Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multi-dimensional scale for assessment of erectile dysfunction. Urology. 1997: 49: 822-830. Go to original source... Go to PubMed...
    14. Abrams P. In support of pressure-flow studies for evaluating men with lower urinary tract symptoms (editorial) see comments. Urology. 1994; 44: 153-155. Go to original source... Go to PubMed...
    15. Eri LM, Wessel N, Berge V. Test-retest variation of pressure flow parameters in men with bladder outlet obstruction. J Urol. 2001; 165: 1188-1192. Go to original source... Go to PubMed...
    16. Lowe FC. Phytotherapy in the management of benign prostatic hyperplasia. Urology. 2001: 58(6 suppl 1): 71-76; discussion 76-77. Go to original source... Go to PubMed...
    17. Lowe FC, Dreikorn K, Borkowski A, et al. Review of placebocontrolled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate. 1998: 37: 187-193. Go to original source...
    18. Feifer AH, Fleshner NE, Klotz L. Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol. 2002; 168: 150-154; discussion 154. Go to original source... Go to PubMed...
    19. Schwinn DA. The role of alpha-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 2001; 88 (suppl 2): 27-34; discussion 49-50. Go to original source... Go to PubMed...
    20. Schwinn DA, Kwatra MM. Expression and regulation of alpha 1-adrenergic receptors in human tissues. Adv Pharmacol. 1998; 42: 390-394. Go to original source...
    21. Smith MS, Schambra UB, Wilson KH, et al. Alphal-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res. 1999: 63: 254-261. Go to original source... Go to PubMed...
    22. McConnell JD. Medical management of benign prostatic hyperplasia with androgen suppression. Prostate Suppl. 1990; 3: 49-59. Go to original source... Go to PubMed...
    23. McConnell JD. The pathophysiology of benign prostatic hyperplasia. J Androl. 1991; 12: 356-363. Go to PubMed...
    24. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alphal-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004; 64: 1081-1088. Go to original source... Go to PubMed...
    25. Gormley GJ, Stoner E., Bruskewitz RC. The effect of finasteride in men with benign prostate hyperplasia. The Finasteride Study Group (see Comments). N Engl J Med 1992; 327: 1185-1191. Go to original source... Go to PubMed...
    26. Russel DW, Wilson JD. Steroid 5 alpha reductase: two genes/two enzymes. Annu Rew Biochem. 1994; 63: 25-61. Go to original source... Go to PubMed...
    27. Thigpen AE, Silver RI. Tissue distribution and ontogens of steroid 5 alpha reductase isoenzyme expresion. J Clin Invest. 1993; 92: 903-910. Go to original source... Go to PubMed...
    28. Aumuller G, Eicheler W, Rennenberg H. Immunocytochemical evidence for differential subcellular localization of 5 alpha reductase isoenzymes in human tissues. Acta Anat (Basel) 1996; 156: 241-252. Go to original source... Go to PubMed...
    29. Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men recieving finasteris before prostatectomy. J Urol 1993; 150: 1736-1739. Go to original source... Go to PubMed...
    30. Steers WD. 5 Alpha reductases activity in the prostate. Urology 2001; 58(suppl 6a): 17-24. Go to original source... Go to PubMed...
    31. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosteron and the concept of 5 alpha reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002; 19: 413-425. Go to original source... Go to PubMed...
    32. Ruggieri MR, Braverman AS, Pontari MA. Combined USB of a-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 2005; 174: 1743-1748. Go to original source... Go to PubMed...
    33. Abrams P, Kaplan S, De Koning Gans HJ, Miliard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 999-1004. Go to original source... Go to PubMed...
    34. Van Kerrenbroeck P, Kreder K, Jonas U, Zinner N, Wein A, for the Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57: 414-421. Go to original source... Go to PubMed...
    35. Cardozo L, Lisec M, Miliard R, Van Vierssen Trip O, KuzminI, Drogendijk TE. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder, J Urol 2004; 172: 1919-1924. Go to original source... Go to PubMed...
    36. Galeo BJ, Galee MA. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. Ann Pharmacother 2008; 42: 111-115. Go to original source... Go to PubMed...
    37. McVary KT, Monnig W, Camps Jr JL, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071-1077. Go to original source... Go to PubMed...
    38. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomized placebo controlled study to assess the efficacy of twice daily Vardenafil in the treatment of LUTS secondary to BPH. Eur Urol 2008; 53: 1236-1244. Go to original source... Go to PubMed...
    39. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wacbs B, Young JM. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-1407. Go to original source... Go to PubMed...
    40. Roehrborn CG, McVary KT, EKon-Mboussa A, Viktim L. Tadalafil administered once a day in the treatment of men with LUTS secondary to BPH; a dose-finding study. J Urol 2008; 180: 1228-1234. Go to original source... Go to PubMed...
    41. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr. GL. Dixon CM, Kusek JW., for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398. Go to original source... Go to PubMed...
    42. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual alpha-reductase inhibitor dutasteride, Eur Urol 2003; 44: 461-466. Go to original source... Go to PubMed...
    43. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, for the Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasterido, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-126. Go to original source... Go to PubMed...
    44. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. NEJM 1996; 335: 533-539. Go to original source... Go to PubMed...
    45. Roehrborn CG, Siami P, Barkin, Damiao R, Major Walkar K. Morrill B., for the Combination of Avodart and Tamsulosin (CombAT) Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-621. Go to original source... Go to PubMed...
    46. McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007; 29: 387-398. Go to original source... Go to PubMed...
    47. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892-900. Go to original source... Go to PubMed...
    48. American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia (BPH). www.auanet. org/guidelines/bph.cfm (updated 2006).
    49. Chamzin A. Kombinovaná léčba BHP-aktuální stav. Urol List 2008; 6(3): 55-58.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.